Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Smart Antibody Medicines: How the ALCO5 Platform Could Upgrade Targeted Cancer Therapy January 23, 2026
- Docetaxel Rechallenge vs Cabazitaxel in mCRPC: VA Cohort Study January 21, 2026
- Phase 3 Trial For Opevesostat A CYP11A1 Inhibitor in mCRPC January 20, 2026
- Newsletter 3/2026 January 18, 2026
KLS-3021: a Promising Oncolytic Virus for Prostate Cancer
/in Oncolytic, Preclinical Research/by MaxKLS-3021 is a novel oncolytic virus therapy developed for the treatment of prostate cancer. It employs a recombinant vaccinia virus engineered to selectively infect and destroy cancer cells while activating the immune system to target tumors more effectively. The virus carries three therapeutic genes: PH-20, which degrades the extracellular matrix to facilitate viral spread and […]
ESMO Congress 2025 Confirms the Role of AI in Cancer Treatment
/in Artificial Intelligence/by MaxAt the ESMO Congress 2025 held in Berlin, artificial intelligence demonstrated a pivotal role in reshaping cancer treatment through novel biomarker applications. Studies presented at this event showed how AI models analyzing pathology images, imaging data, and genomic profiles can improve predictions of patient responses to therapies. For example, in metastatic colorectal cancer, AI identified […]
mRNA-based COVID-19 Vaccines Improve Immunotherapy Outcomes?
/in Retrospective studies/by MaxAt the 2025 ESMO Congress, interesting data was presented showing that mRNA-based COVID-19 vaccines significantly improve outcomes for cancer patients undergoing immunotherapy. This large retrospective study, conducted by MD Anderson Cancer Center in collaboration with the University of Florida, analyzed clinical data from over 1,000 patients with various types of cancer treated between 2019 and […]
Phase 1/2 Trial to Evaluate Gedatolisib Plus Darolutamide Combo in mCRPC
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxGedatolisib, an inhibitor targeting the PI3K/AKT/mTOR pathway, in combination with darolutamide, an androgen receptor antagonist, is being evaluated as a treatment option for metastatic castration-resistant prostate cancer (mCRPC). In a phase 1/2 clinical trial, patients who had progressed on prior androgen receptor signaling inhibitors received once-weekly intravenous gedatolisib in doses of 120 mg or 180 […]
ADVC001: Lead-212 PSMA Alpha Therapy Shows Safety and Efficacy in mCRPC Trial
/in Clinical Trial, Metastatic, Phase 1/by MaxAt the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, new clinical data from a Phase 1b dose escalation trial investigating ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) was presented. The therapy utilizes a radioactive isotope, Lead-212, to deliver targeted alpha radiation to prostate cancer cells, aiming […]
Phase 3 PRESTO Trial Results: Apalutamide Extends Progression Free Survival
/in Clinical Trial, Metastatic, Phase 3/by MaxThe PRESTO trial, a phase 3 open-label study, evaluated androgen blockade intensification in patients with high-risk biochemically relapsed prostate cancer after radical prostatectomy. This population featured rapid PSA doubling times and no detectable metastases. The study randomized 504 patients to 52 weeks of treatment with either androgen deprivation therapy (ADT) alone, ADT plus apalutamide, or […]
ENZARAD Trial Shows Selective Gains for Node-Positive Prostate Cancer With Enzalutamide Intensification
/in Clinical Trial, Metastatic, Phase 3/by MaxThe final results of the phase 3 ENZARAD study, presented at the European Society for Medical Oncology (ESMO) Congress 2025, reveal that intensifying androgen deprivation therapy (ADT) with enzalutamide does not significantly improve metastasis-free survival (MFS) in the overall population of men with high-risk localized or locally advanced prostate cancer. Conducted across eight countries and […]
Pluvicto extends disease control in advanced hormone-sensitive prostate cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxThe Phase III PSMAddition trial presented at the 2025 European Society for Medical Oncology Congress marks a meaningful advance in the treatment of prostate cancer that still responds to hormonal therapy but has already spread to distant sites. In this study, patients with prostate-specific membrane antigen–positive metastatic hormone-sensitive prostate cancer received the radioligand therapy Pluvicto […]